Sodium Benzoate for Treatment of Hepatic Encephalopathy.
Hepatic encephalopathy (HE) is a serious but usually reversible neuropsychiatric complication of cirrhosis, inborn errors of metabolism involving disorders of the urea cycle, and non-cirrhotic portosystemic shunting that most commonly arises from a transjugular intrahepatic portosystemic shunting pr...
| Publicado en: | Gastroenterology & Hepatology Vol. 9; no. 4; pp. 219 - 228 |
|---|---|
| Autores principales: | , , , |
| Formato: | review Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Apr2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=87860747&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 87860747 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15547914 6N5B jtl: Gastroenterology & Hepatology issn: 15547914 maglogo: N pubinfo: dt: Apr2013 vid: 9 iid: 4 pid: 72163 pub: Gastro-Hep Communications, Inc place: New York, New York artinfo: ui: 87860747 87860747 104172983 87860747 ppf: 219 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Sodium Benzoate for Treatment of Hepatic Encephalopathy. aug: au: Misel, Michael L. Gish, Robert G. Patton, Heather Mendler, Michel affil: Pharmacist Specialist for Liver/Kidney Transplant & Hepatology, Center for Abdominal Transplantation/ Department of Pharmacy Services, University of California San Diego Health System, San Diego, CA sug: subj: Hepatic Encephalopathy Drug Therapy Benzoic Acids Administration and Dosage Hepatic Encephalopathy Physiopathology Hepatic Encephalopathy Classification Severity of Illness Benzoic Acids Pharmacodynamics Treatment Outcomes Safety ab: Hepatic encephalopathy (HE) is a serious but usually reversible neuropsychiatric complication of cirrhosis, inborn errors of metabolism involving disorders of the urea cycle, and non-cirrhotic portosystemic shunting that most commonly arises from a transjugular intrahepatic portosystemic shunting procedure. Symptoms can include alterations in cognitive function, neuromuscular activity, and consciousness, as well as sleep disorders and mood changes. HE is associated with significant morbidity and mortality and, if not properly treated, will lead to increased hospital admissions and healthcare costs. Although the standard therapies of lactulose and rifaximin (Xifaxan, Salix) are effective for most patients, these drugs may be associated with significant adverse effects and expense and, in some patients, inadequate therapeutic response. A need for adjunctive therapies exists. Drugs that target serum and tissue ammonia metabolism and elimination may be important adjuncts to drugs that reduce ammonia production and absorption from the gastrointestinal tract for patients with severe or persistent overt symptoms of HE. Sodium benzoate is an inexpensive adjunctive agent that can be used in addition to lactulose and rifaximin and may provide an option for some select patients with refractory HE who have failed to respond to standard therapies or who cannot afford them. Although sodium benzoate does not share the same adverse effect profiles of standard therapies for HE, its efficacy has not been well established. Given the significant dose-dependent sodium content of this therapy, it may not be appropriate for patients with significant fluid retention or kidney dysfunction. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|